TRT Group

Tissue Regeneration Technologies (TRT) is a medical technology company specializing in the development and commercialization of advanced extracorporeal shock wave therapy (ESWT) systems. The company's proprietary SoftWave technology utilizes electrohydraulic acoustic waves to trigger biological responses, including the recruitment of endogenous stem cells and the upregulation of angiogenic growth factors. TRT's devices are FDA-cleared for various applications, including the treatment of chronic pain, musculoskeletal injuries, and the management of diabetic foot ulcers and second-degree burns. Beyond orthopedics and wound care, the company is expanding its reach into urology and aesthetic medicine. TRT operates as a leader in non-invasive regenerative medicine, providing clinicians with tools to accelerate tissue repair and reduce inflammation without surgery or pharmaceuticals.